Zymeworks (NASDAQ: ZYME) — Company Overview, News & Financial Data
Zymeworks is a biotherapeutics company focused on multifunctional therapies for cancer and autoimmune diseases.
Zymeworks
Zymeworks (NYSE:ZYME) is a biotherapeutics company focused on the development and commercialization of next-generation multifunctional biotherapeutics, designed to improve patient outcomes in cancer and autoimmune diseases. The company is versatile in its approach, engaging in the discovery, development, and commercialization of innovative protein-based therapeutics. Zymeworks' projects center around its proprietary platforms which enhance the efficacy and safety of therapeutic antibodies and antibody-drug conjugates. A key objective for Zymeworks is to advance its pipeline of preclinical and clinical candidates, with the ultimate goal of delivering groundbreaking treatments to patients in need.
Snapshot
Operations
Products and/or services of Zymeworks
- Zymeworks' lead product, zanidatamab, is a bispecific antibody targeting HER2 for various cancers.
- The company developed ZW49, a bispecific antibody-drug conjugate for treating HER2-expressing cancers.
- ZYME-83 is a preclinical project aimed at addressing solid tumors through innovative molecular targeting.
- The Azymetric platform enables the development of bispecific and multispecific antibodies for diverse therapeutic applications.
- Zymeworks' Effector Function Enhancement and Control Technology (EFECT) portfolio facilitates the modulation of immune cell interactions.
- Their Immune Modulating Drug Conjugates (IMDCs) technology is designed to enhance the delivery and efficacy of immunotherapies.
Zymeworks executive team
- Kenneth H. GalbraithChairman of the Board, CEO & President
- Paul A. MooreChief Scientific Officer
- Scott PlatshonExecutive VP & Chief Business Officer
- Kristin StaffordExecutive VP & CFO
- Mark HollywoodExecutive VP & COO
Latest news about Zymeworks
Zymeworks signs $813 million licensing deal with Roche
United StatesZymeworks completes $17 per share Theravance deal
United StatesZymeworks receives FDA fast track designation for ZW191 in platinum-resistant ovarian cancer
United StatesZymeworks outlines 2026 priorities with Ziihera Phase 3 success
United States
Key financials
Reported results for Zymeworks , in USD.
- Market cap
- 2.2B
- Revenue (TTM)
- 37.1M
- P/E ratio
- —
- EPS (diluted, TTM)
- -2.0
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 106M | -92.5M | -81.1M | |
| 76.3M | -137.1M | -122.7M | |
| 76M | -138.1M | -118.7M | |
| 412.5M | 130.5M | 124.3M |